HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Recruiting · NCT07137637 · Registry updated 2026-07-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, central nervous system malformation, hematologic disorder, hereditary disease, hereditary sensory and autonomic neuropathy, inherited neurodegenerative disorder, leukemia, myeloid leukemia, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, polyneuropathy | Recruiting | Phase 1 | 2026-07-23 | NCT07137637 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hangzhou Polymed Biopharmaceuticals, Inc. | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Institute of Hematology and Blood Diseases Hospital, Tianjin, China | Tianjin | China | 1 |